v3.26.3
Revenue - Schedule of Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Disaggregation of Revenue [Line Items]        
Revenue $ 24,397 $ 17,601 $ 67,170 $ 45,887
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 15,136 11,300 41,668 30,604
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 9,261 6,301 25,502 15,283
Cardiometabolic Health        
Disaggregation of Revenue [Line Items]        
Revenue 19,764 13,178 53,877 33,729
Cardiometabolic Health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 12,376 8,867 34,041 23,807
Cardiometabolic Health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 7,388 4,311 19,836 9,922
Mounjaro        
Disaggregation of Revenue [Line Items]        
Revenue 10,723 6,515 29,328 15,556
Mounjaro | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 4,998 3,550 14,022 9,508
Mounjaro | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,725 2,965 15,306 6,048
Zepbound        
Disaggregation of Revenue [Line Items]        
Revenue 5,352 3,588 14,440 9,281
Zepbound | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,267 3,568 14,273 9,254
Zepbound | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 86 20 167 28
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 1,578 959 3,924 2,663
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 781 424 1,909 1,116
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 796 535 2,014 1,547
Trulicity        
Disaggregation of Revenue [Line Items]        
Revenue 904 1,052 3,042 3,239
Trulicity | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 601 707 2,109 2,221
Trulicity | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 302 345 932 1,018
Other cardiometabolic health        
Disaggregation of Revenue [Line Items]        
Revenue 1,207 1,064 3,143 2,989
Other cardiometabolic health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 729 618 1,728 1,709
Other cardiometabolic health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 479 446 1,416 1,281
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 2,600 2,408 7,437 6,769
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,518 1,375 4,218 3,840
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,082 1,033 3,219 2,929
Verzenio        
Disaggregation of Revenue [Line Items]        
Revenue 1,511 1,470 4,286 4,118
Verzenio | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 897 880 2,448 2,467
Verzenio | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 614 590 1,838 1,651
Other oncology        
Disaggregation of Revenue [Line Items]        
Revenue 1,089 937 3,151 2,650
Other oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 621 495 1,770 1,373
Other oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 468 443 1,381 1,277
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 1,435 1,362 4,055 3,706
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 801 773 2,211 2,052
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 634 589 1,844 1,654
Taltz        
Disaggregation of Revenue [Line Items]        
Revenue 856 902 2,444 2,511
Taltz | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 539 583 1,495 1,609
Taltz | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 316 318 949 902
Other immunology        
Disaggregation of Revenue [Line Items]        
Revenue 579 461 1,611 1,195
Other immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 262 190 716 444
Other immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 318 271 895 751
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 444 316 1,254 932
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 384 240 1,002 677
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 59 76 253 255
Other        
Disaggregation of Revenue [Line Items]        
Revenue 154 337 546 752
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 57 45 197 227
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 97 $ 292 $ 349 $ 525